DOCK5-IN-C21 is an allosteric inhibitor of the guanine nucleotide exchange factor DOCK5.

CC214-1 is an mTOR inhibitor with potential anticancer activity, inhibits protein translation, and induces autophagy. CC214-1 is an in vitro tool compound for exploring the biology of mTOR kinases and can be used to study myeloma.

MC2184 is the inhibitor of human recombinant SIRT1.

12(Z),15(Z)-Heneicosadienoic acid, an ω-6 very long-chain polyunsaturated fatty acid, serves as a positional isomer of heneicosadienoic acid, which is scarcely found in living organisms.

Buloxibutid (AT2 receptor agonist C21) is a novel and selective small molecule angiotensin II AT2 receptor agonist with Ki values of 0.4 nM and 10 μM for AT2 and AT1 receptors, respectively.

Heneicosanoic acid (C21:0) (HEA) is a fatty acid found in human milk fat. HEA is also a part of the phospholipids of the articular cartilage boundary lubricant. HEA is a constituent of red blood cell fatty acids.

11(Z),14(Z),17(Z)-Eicosatrienoic acid methyl ester is the ester derivative of 11(Z),14(Z),17(Z)-eicosatrienoic acid, identified within lipid-producing microalgae Nannochloropsis, as well as in diesel-contaminated soils and residential wastewater.

ATAC21 is a linker-immune-stimulatory compound created by conjugating a noncleavable maleimide-PEG4 linker, which includes a succinimide group, with an immune-stimulatory agent. This compound can be further conjugated with SBT-040 (anti-CD40 antibody) to form a conjugate [1].

BNC210 (IW-2143) is a α7 nAChR negative allosteric modulator. BNC210 has potent activity in animal models of anxiety and depression.

DRI-C21041 DIEA serves as an inhibitor of CD40/CD40L interaction, exhibiting an inhibitory concentration (IC50) of 0.31 μM. It effectively suppresses the immune response triggered by alloantigen [1].

ONC212, a fluorinated-ONC201 analogue, is a selective agonist of GPR132.

Dri-c21045 showed concentration-dependent inhibition of NF- B activation and all CD40L induced by B cell proliferation. IC50 was 17.1 M and 4.5 M, respectively.Dri-c21045 is an effective selective inhibitor of CD40-CD40L synergistic stimulator protein-pro

NVP-CFC218 is a novel potent and selective p53-HDM2 inhibitor.

CC214-2 is a potent dual inhibitor of mTORC1 and mTORC2, known for its ability to impede autophagy by modulating mammalian target of rapamycin (mTOR) signaling. With this capacity, CC214-2 shows promise in shortening the duration of tuberculosis (TB) [1].

TRC210258 is a TGR5 agonist that acts by decreasing glycemic and dyslipidemic cardiovascular risk in animal models of diabesity.

53BP1-binding protein 1 (53BP1) engages with dimethylated lysine 20 on histone 4 (H4K20me2) through its tandem tudor domains within a homodimer configuration, crucial for the DNA damage response. UNC2170, a micromolar 53BP1 ligand, selectively interacts with this site, demonstrating at least 17-fold preference for 53BP1 over similar proteins. This interaction occurs in a pocket formed by the 53BP1's tudor domains. Moreover, UNC2170 acts as an antagonist to 53BP1 in cellular lysates, effectively inhibiting class switch recombination, a process dependent on the functional 53BP1 tudor domain, thus confirming its cellular activity.

DRI-C21041 is a potent inhibitor of the CD40/CD40L interaction, demonstrating an inhibitory concentration 50 (IC50) value of 0.31 μM. It effectively suppresses the immune response triggered by alloantigen [1].

BSc2118 is a potent proteasome inhibitor. BSc2118 shows significant antimyeloma activity and may be considered as a promising agent in cancer drug development. BSc2118 is also a promising new candidate for stroke therapy, which may in addition alleviate recombinant tissue-plasminogen activator-induced brain toxicity.

Qingyangshengenin (Cynanchagenin) is a steroid used in the preparation of antiepileptic agents.

L 685818 is the C18-hydroxy, C21-ethyl of FK-506 analog.

Selective protein arginine methyltransferase 1 (PRMT1) inhibitor (IC50 = 1.8 μM). Exhibits five-fold selectivity for PRMT1 over PRMT6 and >250-fold selectivity over PRMT3 and CARM1.

Tenacissoside I (Tenacissimoside B),Tenacissosides B, C and marsdenoside K inhibit the proliferation of Raji, NB4 and K562 cells in vitro significantly, in a dose and time dependent manner.

Tenacissoside G is a C21 steroid from the stem of Marsdenia tenacissima. It reverses multidrug resistance in multidrug-resistant cancer cells overexpressing P-glycoprotein.